Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

GeneDx Holdings (WGS) Change in Acquisitions & Divestments (2023 - 2025)

GeneDx Holdings (WGS) has disclosed Change in Acquisitions & Divestments for 2 consecutive years, with $10.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Change in Acquisitions & Divestments fell 37.81% to $10.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $44.0 million, a 7.09% increase, with the full-year FY2025 number at $44.0 million, up 7.09% from a year prior.
  • Change in Acquisitions & Divestments was $10.0 million for Q4 2025 at GeneDx Holdings, up from $7.2 million in the prior quarter.
  • In the past five years, Change in Acquisitions & Divestments ranged from a high of $26.7 million in Q2 2025 to a low of $2.9 million in Q2 2024.